As part of the search for drugs with activity on the central nervous system (CNS) a fluoroaryl-amine was identified and developed by GlaxoSmithKline. The manufacturing process was developed and optimised by following a quality by design approach whereby a control strategy was developed, underpinned by process understanding and risk analysis, for enhanced level of quality assurance. A summary of the overall control strategy for this process includes different elements of control (Quality Process Parameters, control of the Quality Attributes of starting materials, intermediates, solvents, in-process controls). The drug substance Critical Quality Attributes (drug substance-CQAs) related to the genotoxin content, methyl methanesulfonate (methyl mesylate, MMS), ethyl methanesulfonate (ethyl mesylate, EMS) and isopropyl methanesulfonate (isopropyl mesylate, IMS) are identified and discussed in detail to show the process development studies carried out to ensure quality control for the final drug substance. The process understanding developed could allow for the elimination of testing of the genotoxic impurities in the final drug substance.
A fast gradient reversed-phase liquid chromatography (LC) method, using an acetonitrile gradient was developed to determine the chromatographic hydrophobicity index (CHI), as reported by Valco et al. (Anal. Chem. 1997, 69, 2022-2029). The analytical method provides retention times, based on UV detection at two different wavelengths, which then are converted into CHI values after calibration with a set of test compounds. The CHI of each compound is measured at three different pH values, 2.0, 7.4, and 10.5; so using an 8-min gradient at each pH value one compound can be analyzed in approximately 24 min. The aim of this work is to improve the throughput of the CHI screening using a LC/MS approach, so the application of the LC/MS technique is an extension of the LC/UV approach previously reported by Valco et al. This approach allows contemporary injection of N compounds into the LC/MS system, the retention time of each compound can be then extracted from the selected ion recording chromatograms. The throughput of the existing screening method could be increased by N times, where N is the number of compounds injected, so only three runs are needed to determine the CHI at three different pH values for a set of N compounds. The highest value of N depends on the total number of channels that can be monitored simultaneously; in the present work, 32 channels were used. This LC/MS method has been tested for a number of commercial products analyzed as mixtures, and data obtained were compared with those coming from the classical LC/UV approach. In the same way, the method was tested for a number of compounds associated with two GlaxoWellcome projects in the antibacterial area. Data reported show that the LC/MS method can be successfully applied for analyzing compounds in mixtures and for compounds with poor UW absorption, which cannot be analyzed with the standard LC/UV method.
The co-adsorption of sodium dodecyl sulfate (SDS) and sodium dodecylbenzenesulfonate (SDBS), on the 1-decanethiol self-assembled monolayer (SAM)-functionalized polycrystalline gold surface, is investigated by electrochemical techniques. The peak current (cyclic voltammetry) and charge transfer resistance (impedance spectra) variations are measured, concerning the [Fe(CN)6]3−/[Fe(CN)6]4− couple redox process. SDBS is found to yield a more efficient inhibiting barrier (towards the charge transfer process), when compared to the SDS one. Thus, it is suggesting that a higher tendency of SDBS to be co-adsorbed within the 1-decanethiol SAM with respect to SDS
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.